$36.10
arrow_drop_down0.30%Performance History
| Key Stats | |
|---|---|
| Open | $36.55 |
| Prev. Close | $36.22 |
| EPS | 1.07 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 34.71 | 37.89 |
| 52 Week Range | 21.99 | 42.50 |
| Ratios | |
|---|---|
| EPS | 1.07 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
Supernus Pharmaceuticals (SUPN)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Mr. Jack A. Khattar
- Headquarters
- Rockville
- Employees
- 612
- Exchange
- NASDAQ
Keep an eye on Supernus Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Attention-Deficit Hyperactivity Disorder Treatment Market is projected to Reach USD 15.4 Billion, Garnering A 3.1% CAGR from 2024 to 2034 | Report Analysis by Transparency Market Research Inc.
Supernus Pharmaceuticals to Announce Second Quarter 2024 - GlobeNewswire
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics